Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) has confirmed that approximately 130 million doses of its pandemic H1N1 adjuvanted vaccine were shipped to governments in the fourth quarter of 2009.
Subscribe to our email newsletter
These shipments, together with pandemic vaccine products supplied to the US and other governments in the quarter, amount to provisional, unaudited sales of £835 million.
Reportedly, the company is also donating 60 million doses of its vaccine to the WHO for distribution to developing countries. This will be charged as an SG&A cost to GSK in the fourth quarter of 2009.
The company said that the shipments of the vaccine continue to be delivered in the first half of 2010 and it is in ongoing discussions with many governments, as their needs evolve. This includes renegotiation of contracts with governments who have announced changes to their planned immunisation programmes and with governments who have placed new orders for the pandemic vaccine. It is therefore too early to say what the final number of doses supplied and the value of these orders will be.
Following declaration of the pandemic by the World Health Organisation (WHO) in June 2009, the company has been working with governments to respond to their changing needs.